{"id":766265,"date":"2023-06-27T08:36:37","date_gmt":"2023-06-27T12:36:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/"},"modified":"2023-06-27T08:36:37","modified_gmt":"2023-06-27T12:36:37","slug":"journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/","title":{"rendered":"Journal of Clinical Oncology Publishes Results of  Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel monotherapy<\/em><br \/>\n          \n        <\/li>\n<li style=\"margin-bottom:3pt\">\n          <em>Confirmatory Phase 3 ROSELLA trial underway, with planned enrollment of 360 patients in the United States, Europe, Canada, Israel, Asia and South America<\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">MENLO PARK, Calif., June  27, 2023  (GLOBE NEWSWIRE) &#8212; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced publication of the final analysis from its Phase 2 trial evaluating its proprietary cortisol modulator, relacorilant, in women with platinum-resistant ovarian cancer in the <em>Journal of Clinical Oncology (JCO)<\/em>, the premiere journal of the American Society of Clinical Oncology (ASCO).<\/p>\n<p align=\"justify\">The publication is titled <em>Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study <\/em>and can be accessed at the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=564ur350-p0WuOJ4SiRaNbKy8_ZnkMDxKu_lHZeaApMy3xOySSndyDaZgEtX182yULPXt5XTc8ZcpHbG0Qpa2QVx0kFj4-dbDmbhlLy6allOgv_cHU2Ms9Z-kC5s6rXhf2i37JfAe1opW9bEuu83L50ZvEs3WNCBi5FMO8lW9yijQ0-K5J4i7eB-TiciKILteAzMBwFjUhKbHkBJMyHkaOpWF7xPVzeq3OKcyc_TFaeVZbfM1KOcWdu673JrmNaKN7hFI2wxso4GYUGCWPWQOOVBn44SWsGT74DqXRiFajJN1l400wKb_fGbctK9y8JG9kjzqu502pbAlDmO3riscNv3Pxu322sDcMAZLRQez39lD9V5b9eBaw6BS8L9LWZwPnJ9Imbb21XF34vsZ3ExvTU03KZE_Q4HvR18H2GsKNqCiqDmUiqino3xpH_dBDU7W0orCXacXyILYj_u7ClM8oBLAtyee3sNQdGlPfSY5pnO7G0rV-PH9H8h9U2LRbzr_qk7H97GBY1txE69_qLCusMnNmX-2S2AQqmxtfi9qmjqclsugErz-HPSWM4dLTd4TGePsHv-a4kKSdmZ8B0DQErOUIMUvxu7XpKo5bwnFbhadB9KdDRHNmq3iD2eJ19xSI5vl-y0baJ3JocNxLqIXxNNmgEiFYKVYlFbu4gHtKg=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.22.02624<\/a><\/p>\n<p align=\"justify\">In the trial, patients who received relacorilant orally the day before, the day of and the day after their nab-paclitaxel infusion (\u201cintermittent dosing\u201d) experienced a 34 percent reduction in risk of disease progression (median PFS=5.6 vs. 3.8 months, HR 0.66, <em>P<\/em>=0.038), responded to treatment longer (median DoR=5.6 vs. 3.7 months, HR 0.36, <em>P<\/em>=0.006) and had a 33 percent reduction in risk of death (median OS=13.9 vs. 12.2 months, HR 0.67, P=0.066) compared to patients who received nab-paclitaxel alone. Adverse events were comparable across the study arms.<\/p>\n<p align=\"justify\">PFS and OS benefits were exhibited across multiple subgroups of patients. Patients who would have met the eligibility requirements for Corcept\u2019s confirmatory Phase 3 ROSELLA trial did especially well. A post-hoc analysis showed that patients who had received prior bevacizumab, did not have primary platinum-refractory disease and who had received no more than three prior lines of therapy experienced a 62 percent reduction in risk of death (median OS=17.9 vs. 12.6 months, HR 0.38, P=0.011) compared to similar patients who received nab-paclitaxel alone.<\/p>\n<p align=\"justify\">\u201cOutcomes for patients with platinum-resistant ovarian cancer are poor and treatment options are limited,\u201d said first author of the publication Nicoletta Colombo, MD, PhD, Associate Professor, Obstetrics and Gynecology, University of Milan-Bicocca, Director, Ovarian Cancer Center, and Chair, Program of Gynecology, European Institute of Oncology, IRCCS, Milan Italy. \u201cThe benefits experienced by patients in the intermittent dosing group are meaningful especially given the simple, oral dosing and favorable safety profile of relacorilant. We are on the cusp of developing an entirely new way to treat this serious disease.\u201d<\/p>\n<p align=\"justify\">\u201cWe are excited by the data from our Phase 2 trial and enthusiastic the results have been published in the Journal of Clinical Oncology. Our single goal is to replicate the great results seen in our phase 2 trial,\u201d said Bill Guyer, PharmD, Corcept\u2019s Chief Development Officer. \u201cWe believe relacorilant has the potential to become a new standard of care for all patients with platinum-resistant ovarian cancer.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Platinum-Resistant Ovarian Cancer<\/strong>\n      <\/p>\n<p align=\"justify\">Ovarian cancer is the fifth most common cause of cancer death in women.\u00a0Patients whose disease returns less than six months after receiving platinum-containing therapy are described as having \u201cplatinum-resistant\u201d disease. In\u00a0the United States, approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year.\u00a0There are few treatment options and median overall survival following recurrence of disease is typically 12 months or less with single-agent chemotherapy.<\/p>\n<p align=\"justify\">\n        <strong>About Corcept\u2019s Oncology Programs<\/strong>\n      <\/p>\n<p align=\"justify\">There is substantial evidence that cortisol activity at the glucocorticoid receptor (\u201cGR\u201d) allows certain solid tumors to resist treatment and that modulating cortisol\u2019s activity may help anti-cancer treatments achieve their intended effect.<\/p>\n<p align=\"justify\">Many types of solid tumors express the GR and are potential targets for cortisol modulation therapy. In some cancers, cortisol inhibits cellular apoptosis \u2013 the tumor-killing effect many treatments are meant to stimulate. In other cancers, cortisol activity promotes tumor growth. Cortisol also suppresses the body\u2019s immune response; activating \u2013 not suppressing \u2013 the immune system is beneficial in fighting certain cancers.<\/p>\n<p align=\"justify\">Corcept is conducting clinical trials of its proprietary selective cortisol modulators in combination with three different anti-cancer treatments in patients with ovarian, adrenal and prostate cancers.<\/p>\n<p align=\"justify\">\n        <strong>About Relacorilant<\/strong>\n      <\/p>\n<p align=\"justify\">Relacorilant is a non-steroidal, selective glucocorticoid receptor modulator that does not bind to the body&#8217;s other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, including ovarian, adrenal and prostate cancer and Cushing\u2019s syndrome. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents, as well as orphan drug designation in\u00a0the United States\u00a0for the treatment of pancreatic cancer and both\u00a0the United States\u00a0and the\u00a0European Union\u00a0for the treatment of Cushing\u2019s syndrome.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Corcept Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company\u2019s leading selective cortisol modulators as potential treatments for patients with serious disorders \u2013 Cushing\u2019s syndrome, ovarian, prostate and adrenal cancer, ALS, post-traumatic stress disorder and liver disease. Corcept\u2019s drug Korlym<sup>\u00ae<\/sup> was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing\u2019s syndrome.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties include, but are not limited to, our ability to operate our business, conduct our clinical trials and achieve our other goals during the COVID-19 pandemic; risks related to the development of relacorilant and other product candidates, including their clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. These and other risks are set forth in our\u00a0SEC\u00a0filings, which are available at our website and the SEC\u2019s website.<\/p>\n<p align=\"justify\">In this press release, forward-looking statements include those concerning the development of relacorilant as a treatment for ovarian cancer, including its clinical attributes, regulatory approvals, mandates, oversight, and other requirements; the potential for relacorilant plus nab-paclitaxel to become a standard of care for patients with recurrent platinum-resistant ovarian cancer; and our Phase 3 ROSELLA trial. We disclaim any intention or duty to update forward-looking statements made in this press release.<\/p>\n<p align=\"justify\">\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>Corcept Therapeutics<br \/>For Investor inquiries:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DNMhSbk75C-hPpg9BEbfkAyBD2pFKe1Owa_ARgrVMUh8TB3ppqVUTxUdk0CHiKU9qTGxhFDQQeKymky4xZa40A==\" rel=\"nofollow noopener\" target=\"_blank\">ir@corcept.com<\/a><br \/>For Media inquiries:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lwtlrE1nVhiYciXk5SzjGIy2sv32c4vZ05s8Jzj9nUIaIDjWB5h5ryo2lor9FjE96GSXStx2Vup8KeGnWTZPDluN58A4-H19H2SIpTCDJ0EOuvb6xXPn5bqn9R66yfjbbXuyapPKl0B3OJhyOgxhPQ==\" rel=\"nofollow noopener\" target=\"_blank\">CorceptCommunications@corcept.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c7Mu_ptUckK-Nuasp9vvPDbYDlZQRzRRGxY9qcAopza4Q1gzNeeyYQL3uQzKP4CRHYXk520rOCNb71kwylvjPw==\" rel=\"nofollow noopener\" target=\"_blank\">www.corcept.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NGUzZDRmNmItMWUyZC00NjliLWEwNmItYWQzOTEyODAyOGUxLTExMDE2NTc=\/tiny\/Corcept-Therapeutics-Incorpora.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel monotherapy Confirmatory Phase 3 ROSELLA trial underway, with planned enrollment of 360 patients in the United States, Europe, Canada, Israel, Asia and South America MENLO PARK, Calif., June 27, 2023 (GLOBE NEWSWIRE) &#8212; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced publication of the final analysis from its Phase 2 trial evaluating its proprietary cortisol modulator, relacorilant, in women with platinum-resistant ovarian cancer in the Journal of Clinical Oncology (JCO), the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Journal of Clinical Oncology Publishes Results of  Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-766265","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel monotherapy Confirmatory Phase 3 ROSELLA trial underway, with planned enrollment of 360 patients in the United States, Europe, Canada, Israel, Asia and South America MENLO PARK, Calif., June 27, 2023 (GLOBE NEWSWIRE) &#8212; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced publication of the final analysis from its Phase 2 trial evaluating its proprietary cortisol modulator, relacorilant, in women with platinum-resistant ovarian cancer in the Journal of Clinical Oncology (JCO), the &hellip; Continue reading &quot;Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-27T12:36:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer\",\"datePublished\":\"2023-06-27T12:36:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/\"},\"wordCount\":1098,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/\",\"name\":\"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=\",\"datePublished\":\"2023-06-27T12:36:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer - Market Newsdesk","og_description":"Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel monotherapy Confirmatory Phase 3 ROSELLA trial underway, with planned enrollment of 360 patients in the United States, Europe, Canada, Israel, Asia and South America MENLO PARK, Calif., June 27, 2023 (GLOBE NEWSWIRE) &#8212; Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced publication of the final analysis from its Phase 2 trial evaluating its proprietary cortisol modulator, relacorilant, in women with platinum-resistant ovarian cancer in the Journal of Clinical Oncology (JCO), the &hellip; Continue reading \"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-27T12:36:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer","datePublished":"2023-06-27T12:36:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/"},"wordCount":1098,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/","name":"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=","datePublished":"2023-06-27T12:36:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2NDkxOSM1NjY1NjIzIzIwOTAwODY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/journal-of-clinical-oncology-publishes-results-of-corcepts-phase-2-trial-of-relacorilant-in-women-with-platinum-resistant-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Journal of Clinical Oncology Publishes Results of Corcept\u2019s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/766265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=766265"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/766265\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=766265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=766265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=766265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}